GSK plans to assess rheumatoid arthritis drug otilimab for Covid-19

8th May 2020 (Last Updated May 8th, 2020 13:26)

GlaxoSmithKline (GSK) is set to trial an investigational rheumatoid arthritis drug otilimab for the treatment of pneumonia caused by Covid-19 infection.

GSK identified the drug after screening its portfolio and pipeline for potential against Covid-19. The company acquired the rights to otilimab from German biotech firm Morphosys in 2013, noted Reuters.

According to a company spokesman, otilimab could potentially ease the effect of the coronavirus on the lungs but not suppress it directly.